AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Eli Lilly logo
Eli LillyLLY · NYSE
73 assets: 30 approved, 12 Ph 3, 16 Ph 2, 12 Ph 1, 3 othereloralintidePhase 3 · ObesityReliable signalNov 2026Tirzepatide (Zepbound) · Phase 3$1.30T$4.9BSep 2026Cash-flow positive$15.4B
Johnson & Johnson logo
Johnson & JohnsonJNJ · NYSE
57 assets: 31 approved, 11 Ph 3, 4 Ph 2, 11 Ph 1SeltorexantPhase 3 · Major Depressive DisorderReliable signal8 Dec 2026Milvexian · Phase 3$656.5B$17.2BSep 2026Cash-flow positive$16.1B
AbbVie logo
AbbVieABBV · NYSE
78 assets: 22 approved, 9 Ph 3, 12 Ph 2, 25 Ph 1, 10 othermesalamine (Asacol HD)US approval withdrawn · Ulcerative ColitisReliable signalNov 2026Budigalimab · Phase 2$505.6B$10.8BSep 2026Cash-flow positive$10.0B
Merck & Co. logo
Merck & Co.MRK · NYSE
54 assets: 19 approved, 19 Ph 3, 10 Ph 2, 3 Ph 1, 3 otherEnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signalNov 2026Sacituzumab Tirumotecan · Phase 3$339.7B$9.8BSep 2026Cash-flow positive$30.8B
Novartis logo
NovartisNVS · NYSE
89 assets: 32 approved, 13 Ph 3, 24 Ph 2, 12 Ph 1, 8 otherindacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal27 Nov 2026Inclisiran · Approved$294.9B$11.5BDec 2025Cash-flow positive$11.2B
AstraZeneca logo
AstraZenecaAZN · Nasdaq
114 assets: 36 approved, 26 Ph 3, 28 Ph 2, 20 Ph 1, 4 otherelecoglipronPhase 3 · ObesityReliable signal24 Nov 2026AZD0754 · Phase 1/2$277.3B$7.6BMar 2026—$14.6B
Amgen logo
AmgenAMGN · Nasdaq
29 assets: 18 approved, 6 Ph 3, 2 Ph 2, 3 Ph 1Denosumab (Xgeva)Phase 3 · Multiple MyelomaReliable signal14 Dec 2026Abp 234 · Phase 3$240.1B$13.2BSep 2026Cash-flow positive$7.8B
Gilead Sciences logo
Gilead SciencesGILD · Nasdaq
27 assets: 13 approved, 7 Ph 3, 5 Ph 2, 2 Ph 1filgotinibPhase 3 · Rheumatoid ArthritisReliable signalDec 2026Sacituzumab Govitecan · Phase 3$209.6B$6.4BSep 2026Cash-flow positive$6.3B
A
AbbottABT · NYSE
1 asset: 1 Ph 3SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal30 Dec 2026Serplulimab · Phase 1$181.0B$4.3BSep 2026Cash-flow positive$3.3B
Novo Nordisk logo
Novo NordiskNVO · NYSE
32 assets: 13 approved, 8 Ph 3, 5 Ph 2, 4 Ph 1, 2 otherrepaglinideUS approval withdrawn · Type 2 DiabetesPartial signalDec 2026UBT251 · Phase 1$174.4B$4.2BDec 2025Cash-flow positive$7.9B
Pfizer logo
PfizerPFE · NYSE
95 assets: 43 approved, 19 Ph 3, 9 Ph 2, 13 Ph 1, 11 otherecnoglutidePhase 3 · ObesityReliable signal29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3$159.9B$11.0BSep 2026Cash-flow positive$11.5B
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX · Nasdaq
15 assets: 7 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 1 otherPovetaciceptPhase 3 · IgA Nephropathy15 Dec 2026VX-407 · Phase 1$136.0B$6.3BSep 2026Cash-flow positive$4.2B
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY · NYSE
61 assets: 23 approved, 9 Ph 3, 18 Ph 2, 9 Ph 1, 2 otherMezigdomidePhase 3 · Multiple MyelomaPartial signalNov 2026Izalontamab brengitecan · Phase 3$121.9B$12.6BSep 2026Cash-flow positive$10.6B
Sanofi logo
SanofiSNY · Nasdaq
63 assets: 23 approved, 8 Ph 3, 12 Ph 2, 5 Ph 1, 15 otherGemigliptinPhase 3 · Type 2 DiabetesReliable signal25 Nov 2026rilzabrutinib · Phase 3$113.5B$6.3BMar 2026—$9.0B
GlaxoSmithKline logo
GlaxoSmithKlineGSK · NYSE
73 assets: 26 approved, 8 Ph 3, 10 Ph 2, 10 Ph 1, 19 otherVilanterolPhase 3 · AsthmaPartial signal23 Nov 2026Dostarlimab · Phase 2$104.8B$4.6BDec 2025Cash-flow positive$9.9B
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN · Nasdaq
51 assets: 8 approved, 10 Ph 3, 23 Ph 2, 9 Ph 1, 1 otherFreneslerbart/mevonlerbartPhase 3 · Allergic ConjunctivitisReliable signal4 Dec 2026ALN-ANG3 · Phase 1$97.4B$9.3BSep 2026Cash-flow positive$6.6B
Moderna logo
ModernaMRNA · Nasdaq
4 assets: 2 approved, 1 Ph 3, 1 Ph 2Intismeran AutogenePhase 3 · Non-Small Cell Lung Cancer11 Dec 2026elasomeran · Approved$79.6B$5.2BSep 2026~11.6 qtrs$2.7B
Takeda Pharmaceutical Company logo
Takeda Pharmaceutical CompanyTAK · NYSE
42 assets: 20 approved, 12 Ph 3, 6 Ph 2, 2 Ph 1, 2 otherzasocitinibPhase 3 · Psoriatic ArthritisReliable signalNov 2026Mirvetuximab soravtansine · Phase 2$67.7B—Profitable$4.1B
Teva Pharmaceutical Industries logo
Teva Pharmaceutical IndustriesTEVA · NYSE
13 assets: 10 approved, 2 Ph 3, 1 Ph 1Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal15 Jan 2027Emrusolmin · Phase 1$49.8B$4.1BSep 2026Cash-flow positive$1.8B
BeOne Medicines logo
BeOne MedicinesONC · Nasdaq
10 assets: 6 approved, 2 Ph 3, 2 Ph 1BGB-43395Phase 3 · HR+/HER2- Metastatic Breast CancerNov 2026Sonrotoclax · Phase 2$44.9B$5.9BSep 2026Cash-flow positive$2.4B
Biogen logo
BiogenBIIB · Nasdaq
20 assets: 11 approved, 4 Ph 3, 3 Ph 2, 2 otherLitifilimabPhase 3 · Systemic Lupus ErythematosusReliable signal1 Dec 2026Felzartamab · Phase 3$37.2B$1.3BSep 2026Cash-flow positive$2.2B
Revolution Medicines logo
Revolution MedicinesRVMD · Nasdaq
5 assets: 1 approved, 1 Ph 3, 1 Ph 2, 2 Ph 1ZoldonrasibPhase 3 · Non-Small Cell Lung Cancer31 Dec 2026Zoldonrasib · Phase 1$34.6B$3.7BSep 2026~10.2 qtrs$1.5B
Genmab logo
GenmabGMAB · Nasdaq
8 assets: 4 approved, 1 Ph 3, 2 Ph 2, 1 Ph 1Rinatabart sesutecan (Rina-S)Phase 3 · Ovarian Cancer31 Dec 2026Zenocutuzumab · Phase 2$31.8B—Cash-flow positive$1.4B
Insmed Incorporated logo
Insmed IncorporatedINSM · Nasdaq
1 asset: 1 Ph 2OpSCFPhase 2 · Atopic DermatitisPartial signalNone on record$26.3B$1.1BSep 2026~7.7 qtrs$944M
United Therapeutics logo
United TherapeuticsUTHR · Nasdaq
7 assets: 6 approved, 1 Ph 3RalinepagPhase 3 · Pulmonary Arterial HypertensionReliable signalDec 2026Ralinepag · Phase 3$24.6B$2.1BSep 2026Cash-flow positive$703M
Incyte logo
IncyteINCY · Nasdaq
13 assets: 9 approved, 4 Ph 3INCA033989Phase 3 · Essential Thrombocythemia9 Dec 2026Ruxolitinib (Opzelura) · Phase 1$24.0B$3.9BSep 2026Cash-flow positive$3.4B
Viatris logo
ViatrisVTRS · Nasdaq
13 assets: 13 approvedApproved assets onlyJan 2027Sotagliflozin (Inpefa) · Phase 3$23.3B$1.8BSep 2026Cash-flow positive~$979M
BioNTech logo
BioNTechBNTX · Nasdaq
9 assets: 4 Ph 3, 3 Ph 2, 2 Ph 1Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signalNov 2026Beruzatatug pelitecan · Phase 2$21.1B$9.0BDec 2025Cash-flow positive$2.4B
Alnylam Pharmaceuticals logo
Alnylam PharmaceuticalsALNY · Nasdaq
15 assets: 6 approved, 4 Ph 3, 3 Ph 2, 2 Ph 1ZilebesiranPhase 3 · HypertensionReliable signal27 Nov 2026Inclisiran · Approved$19.8B$3.6BSep 2026Cash-flow positive$1.5B
Exelixis logo
ExelixisEXEL · Nasdaq
5 assets: 2 approved, 1 Ph 3, 2 Ph 1ZanzalintinibPhase 3 · Colorectal Cancer23 Nov 2026XB010 · Phase 1$16.7B$892MOct 2026Cash-flow positive~$821M
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX · Nasdaq
6 assets: 3 approved, 2 Ph 3, 1 Ph 2DireclidinePhase 3 · SchizophreniaPartial signalJul 2027Osavampator · Phase 3$16.5B$744MSep 2026Cash-flow positive$1.2B
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ · Nasdaq
8 assets: 7 approved, 1 Ph 3Cannabidiol (JZP926)Phase 2/3 · Epilepsy31 Dec 2026Zanidatamab · Phase 2$15.5B$2.9BSep 2026Cash-flow positive$829M
BridgeBio Pharma logo
BridgeBio PharmaBBIO · Nasdaq
1 asset: 1 approvedApproved assets only17 Sep 2027Acoramidis · Approved$15.2B$1.5BSep 2026~16.7 qtrs$536M
Dr. Reddy's Laboratories logo
Dr. Reddy's LaboratoriesRDY · NYSE
4 assets: 2 approved, 2 Ph 3PyrotinibPhase 3 · Non-Small Cell Lung CancerPartial signalNov 2026Pyrotinib · Phase 1/2$12.5B$172MMar 2025Cash-flow positive$323M
Kymera Therapeutics logo
Kymera TherapeuticsKYMR · Nasdaq
1 asset: 1 Ph 2KT-621Phase 2 · Atopic DermatitisWeak signalApr 2027KT-621 · Phase 1$12.3B$971MSep 2026~13.5 qtrs$430M
BioMarin Pharmaceutical logo
BioMarin PharmaceuticalBMRN · Nasdaq
10 assets: 8 approved, 1 Ph 3, 1 Ph 2BMN 333Phase 2/3 · Achondroplasia31 Dec 2026Migalastat · Phase 3$11.9B$736MSep 2026Cash-flow positive$988M
Spyre Therapeutics logo
Spyre TherapeuticsSYRE · Nasdaq
4 assets: 4 Ph 2SPY003Phase 2 · Ulcerative ColitisPartial signalJun 2027SPY001 · Phase 2$9.6B$1.1BSep 2026~24.1 qtrswith a later raise$260M
Madrigal Pharmaceuticals logo
Madrigal PharmaceuticalsMDGL · Nasdaq
4 assets: 1 approved, 1 Ph 2, 1 Ph 1, 1 otherErvogastatPhase 2 · MASH / NASHPartial signalDec 2026Resmetirom · Phase 3$9.2B$962MSep 2026~24.5 qtrs$388M
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX · Nasdaq
4 assets: 4 Ph 3ElsunersenPhase 3 · EpilepsyPartial signalDec 2026Relutrigine · Phase 3$8.5B$745MSep 2026~9.3 qtrs$289M
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX · Nasdaq
2 assets: 2 approvedApproved assets only10 Feb 2027icotrokinra · Phase 3$8.3B$800MSep 2026Cash-flow positive$176M
Rhythm Pharmaceuticals logo
Rhythm PharmaceuticalsRYTM · Nasdaq
3 assets: 1 approved, 2 Ph 2bivamelagonPhase 2 · Hypothalamic ObesityPartial signal13 Mar 2027setmelanotide · Phase 3$8.3B$321MSep 2026~15.7 qtrs$180M
Corcept Therapeutics logo
Corcept TherapeuticsCORT · Nasdaq
4 assets: 2 approved, 2 Ph 2miricorilantPhase 2 · MASH / NASHPartial signalDec 2026Relacorilant (Lifyorli) · Phase 2$7.4B$371MSep 2026Cash-flow positive$242M
Abivax logo
AbivaxABVX · Nasdaq
1 asset: 1 Ph 3obefazimodPhase 3 · Ulcerative ColitisReliable signalDec 2026obefazimod · Phase 2$7.3B$460MJun 2026~13.8 qtrswith a later raise$216M
ImmunityBio logo
ImmunityBioIBRX · Nasdaq
2 assets: 1 approved, 1 Ph 1HankPhase 1 · Non-Small Cell Lung CancerNov 2026Nogapendekin alfa inbakicept (Anktiva) · Phase 2$7.1B$334MSep 2026~4.7 qtrs$190M
Axsome Therapeutics logo
Axsome TherapeuticsAXSM · Nasdaq
6 assets: 3 approved, 2 Ph 3, 1 Ph 2ReboxetinePhase 3 · NarcolepsyPartial signalDec 2026Solriamfetol · Phase 3$7.0B$314MSep 2026~15.4 qtrs$198M
Immunovant, Inc. logo
Immunovant, Inc.IMVT · Nasdaq
1 asset: 1 Ph 3ImeroprubartPhase 3 · Myasthenia GravisMay 2027Imeroprubart · Phase 2$6.9B$722MSep 2026~7.2 qtrs~$441M
Oruka Therapeutics logo
Oruka TherapeuticsORKA · Nasdaq
2 assets: 2 Ph 2AvrukibartPhase 2 · PsoriasisPartial signalOct 2027ORKA-002 · Phase 2$6.5B$920MSep 2026~29.8 qtrs$154M
Kodiak Sciences Inc. logo
Kodiak Sciences Inc.KOD · Nasdaq
3 assets: 3 Ph 3Tarcocimab tedromerPhase 3 · Age-Related Macular DegenerationReliable signalFeb 2027Tabirafusp alfa · Phase 3$6.4B$89MSep 2026~2.1 qtrs$208M
Cytokinetics logo
CytokineticsCYTK · Nasdaq
4 assets: 1 approved, 1 Ph 3, 1 Ph 2, 1 otherOmecamtiv mecarbilPhase 3 · Heart FailureReliable signalSep 2027Omecamtiv mecarbil · Phase 3$6.4B$1.1BSep 2026~7.9 qtrs$397M
Arrowhead Pharmaceuticals logo
Arrowhead PharmaceuticalsARWR · Nasdaq
16 assets: 1 approved, 3 Ph 3, 10 Ph 2, 2 Ph 1OlpasiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal31 Dec 2026SRP-1003 · Phase 1/2$6.1B$1.2BSep 2026~17.5 qtrs$739M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM · Nasdaq
2 assets: 1 approved, 1 Ph 2volixibatPhase 2 · Primary Sclerosing CholangitisJan 2027volixibat · Phase 2$6.0B$374MSep 2026~5.5 qtrs$347M
Legend Biotech Corporation logo
Legend Biotech CorporationLEGN · Nasdaq
2 assets: 1 approved, 1 otherLCAR-F33SMultiple Myeloma26 Feb 2027Ciltacabtagene autoleucel · Phase 2$6.0B$902MDec 202510+ yearswith a later raise$415M
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND · Nasdaq
2 assets: 1 approved, 1 Ph 2VK2809Phase 2 · MASH / NASHPartial signalNone on record$6.0B$495MSep 2026Cash-flow positive$23M
Scholar Rock logo
Scholar RockSRRK · Nasdaq
1 asset: 1 approvedApproved assets onlyJun 2028apitegromab · Phase 2$5.9B$417MSep 2026~5.4 qtrs$211M
Gossamer Bio logo
Gossamer BioGOSS · Nasdaq
1 asset: 1 Ph 3SeralutinibPhase 3 · Pulmonary Arterial HypertensionPartial signalDec 2026Seralutinib · Phase 3$5.6B$51MSep 2026~1.3 qtrs$137M
Liquidia Corporation logo
Liquidia CorporationLQDA · Nasdaq
2 assets: 1 approved, 1 Ph 3Treprostinil (L606)Phase 3 · Pulmonary Arterial HypertensionFeb 2027Treprostinil (Yutrepia, Liquidia) · Phase 2$5.1B$396MSep 2026Cash-flow positive$72M
PTC Therapeutics logo
PTC TherapeuticsPTCT · Nasdaq
5 assets: 2 approved, 2 Ph 3, 1 Ph 2VolanesorsenPhase 3 · Familial Chylomicronemia SyndromeReliable signal31 Dec 2027Vatiquinone (PTC743) · Phase 3$5.0B$2.1BSep 2026Cash-flow positive$439M
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT · Nasdaq
3 assets: 1 Ph 3, 2 Ph 1bezuclastinibPhase 3 · Gastrointestinal Stromal TumorMay 2028CGT4255 · Phase 1$4.8B$792MSep 2026~9.8 qtrs$297M
Erasca logo
ErascaERAS · Nasdaq
1 asset: 1 Ph 2ERAS-0015Phase 2 · Non-Small Cell Lung Cancer1 May 2028ERAS-0015 · Phase 1$4.8B$644MSep 2026~23.6 qtrs$134M
T
Travere Therapeutics, Inc.TVTX · Nasdaq
1 asset: 1 approvedApproved assets onlyMar 2027sparsentan · Approved$4.8B$303MSep 2026Cash-flow positive$246M
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH · Nasdaq
1 asset: 1 Ph 1LBL-047Phase 1 · Systemic Lupus Erythematosus16 Dec 2027LBL-047 · Phase 1$4.7B$838MSep 2026~19.1 qtrs$189M
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS · Nasdaq
20 assets: 6 approved, 6 Ph 3, 6 Ph 2, 1 Ph 1, 1 otherInotersenUS approval withdrawn · Transthyretin Amyloidosis with PolyneuropathyReliable signalDec 2026Donidalorsen · Phase 3$4.6B$1.9BSep 2026~13.8 qtrs$916M
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP · Nasdaq
4 assets: 1 approved, 2 Ph 2, 1 Ph 1SRSD107Phase 2 · Atherosclerotic Cardiovascular DiseaseJun 2027CTX310 · Phase 1$3.9B$2.3BSep 2026~24.3 qtrs$291M
Tango Therapeutics logo
Tango TherapeuticsTNGX · Nasdaq
2 assets: 2 Ph 2TNG456Phase 1/2 · Non-Small Cell Lung Cancer31 Mar 2027TNG456 · Phase 1/2$3.7B$978MSep 2026~26.1 qtrs$152M
Structure Therapeutics logo
Structure TherapeuticsGPCR · Nasdaq
1 asset: 1 Ph 3aleniglipronPhase 3 · ObesityPartial signalAug 2027aleniglipron · Phase 1$3.7B$1.2BSep 2026~18.3 qtrs$370M
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE · Nasdaq
1 asset: 1 Ph 3AzetukalnerPhase 3 · Major Depressive DisorderReliable signalJan 2027Azetukalner · Phase 3$3.6B$951MSep 2026~10.7 qtrs$371M
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY · Nasdaq
2 assets: 1 approved, 1 Ph 3ZovegalisibPhase 3 · HR+/HER2- Metastatic Breast Cancer30 Apr 2027Zovegalisib · Phase 1$3.6B$125MSep 2026~2.3 qtrs$280M
Sellas Life Sciences Group logo
Sellas Life Sciences GroupSLS ·
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1Galinpepimut-SPhase 3 · Acute Myeloid LeukemiaWeak signal30 Dec 2026Tambiciclib · Phase 1/2$3.6B$135MSep 2026~19.8 qtrs$23M
Arcutis Biotherapeutics logo
Arcutis BiotherapeuticsARQT · Nasdaq
3 assets: 2 approved, 1 Ph 1ARQ-234Phase 1 · Atopic DermatitisApr 2028ARQ-234 · Phase 1$3.5B$260MSep 2026Cash-flow positive$81M
Denali Therapeutics logo
Denali TherapeuticsDNLI · Nasdaq
4 assets: 1 approved, 1 Ph 3, 1 Ph 2, 1 Ph 1BIIB122 / DNL151 (LRRK2 inhibitor)Phase 3 · Parkinson's DiseasePartial signalFeb 2027DNL628 · Phase 1$3.5B$519MSep 2026~4.7 qtrs$405M
Iovance Biotherapeutics logo
Iovance BiotherapeuticsIOVA · Nasdaq
5 assets: 2 approved, 3 Ph 2LN-145Phase 2 · Non-Small Cell Lung CancerWeak signalSep 2027IOV-4001 · Phase 1/2$3.5B$382MSep 2026~8.1 qtrs$240M
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX · Nasdaq
1 asset: 1 Ph 3avexitidePhase 3 · Post-Bariatric HypoglycemiaPartial signalNone on record$3.4B$768MSep 2026~23.7 qtrs$101M
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN · Nasdaq
10 assets: 7 approved, 3 Ph 2SPN-820Phase 2 · Major Depressive DisorderPartial signalDec 2026viloxazine · Phase 3$3.4B$361MSep 2026Cash-flow positive$122M
Viking Therapeutics logo
Viking TherapeuticsVKTX · Nasdaq
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1VK2735Phase 3 · ObesityReliable signalMay 2027VK2735 · Phase 1$3.3B$960MSep 2026~8.3 qtrs$586M
Bausch Health logo
Bausch HealthBHC · NYSE
15 assets: 13 approved, 1 Ph 3, 1 Ph 2Rifaximin SSDPhase 320 Apr 2027Rifaximin (Xifaxan) · Approved$3.3B$2.5BSep 2026Cash-flow positive$638M
Definium Therapeutics logo
Definium TherapeuticsDFTX · Nasdaq
1 asset: 1 Ph 3Lysergide tartrate (LSD)Phase 3 · Major Depressive DisorderReliable signalSep 2027Lysergide tartrate (LSD) · Phase 3$3.2B$1.0BSep 2026~21.9 qtrs$170M
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD · Nasdaq
4 assets: 2 approved, 1 Ph 3, 1 Ph 2RemlifanserinPhase 3 · Alzheimer's DiseaseAug 2027ACP-211 · Phase 2$3.1B$976MSep 2026Cash-flow positive$319M
Vericel Corporation logo
Vericel CorporationVCEL · Nasdaq
1 asset: 1 approvedApproved assets onlyFeb 2030autologous cultured chondrocytes on porcine collagen membrane · Phase 3$3.0B$170MSep 2026Cash-flow positive$30M
Disc Medicine logo
Disc MedicineIRON · Nasdaq
3 assets: 1 Ph 3, 2 Ph 2BitopertinPhase 3 · Erythropoietic ProtoporphyriaPartial signalMay 2027Selcodebart · Phase 1/2$3.0B$683MSep 2026~14.4 qtrs$183M
Silence Therapeutics logo
Silence TherapeuticsSLN · Nasdaq
1 asset: 1 Ph 2ZerlasiranPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record$2.8B$248MSep 2026~22.4 qtrs$36M
Celcuity Inc. logo
Celcuity Inc.CELC · Nasdaq
1 asset: 1 approvedApproved assets onlyJan 2028Gedatolisib · Phase 1/2$2.7B$643MSep 2026~12.1 qtrs$139M
Xencor logo
XencorXNCR · Nasdaq
6 assets: 1 approved, 1 Ph 2, 4 Ph 1XmAb942Phase 1/2 · Ulcerative ColitisFeb 2027XmAb819 · Phase 1$2.6B$383MSep 2026~8.9 qtrs$286M
IDEAYA Biosciences logo
IDEAYA BiosciencesIDYA · Nasdaq
6 assets: 1 Ph 3, 2 Ph 2, 3 Ph 1DarovasertibPhase 3 · Uveal MelanomaPartial signal7 Jan 2027Tuvutromstat · Phase 1$2.6B$840MSep 2026~9.7 qtrs$413M
HUTCHMED logo
HUTCHMEDHCM · Nasdaq
2 assets: 1 approved, 1 Ph 3SavolitinibPhase 3 · Non-Small Cell Lung CancerPartial signal18 Jan 2027Savolitinib · Phase 2$2.4B$1.4BDec 202510+ years$148M
NewAmsterdam Pharma logo
NewAmsterdam PharmaNAMS · Nasdaq
2 assets: 2 Ph 3ObicetrapibPhase 3 · Type 2 DiabetesPartial signalNov 2026Obicetrapib · Phase 3$2.3B$628MSep 2026~16.7 qtrs$158M
Arcus Biosciences logo
Arcus BiosciencesRCUS · Nasdaq
4 assets: 2 Ph 3, 2 Ph 1CasdatifanPhase 3 · Clear Cell Renal Cell CarcinomaMay 2027Casdatifan · Phase 1$2.3B$630MSep 2026~15.9 qtrs$473M
Lakefront Biotherapeutics NV logo
Lakefront Biotherapeutics NVLKFT · Nasdaq
1 asset: 1 Ph 3Gamgertamig (CM336)Phase 3 · Multiple MyelomaDec 2026Gamgertamig (CM336) · Phase 1/2$2.2B$3.4BMar 2026—$364M
Beam Therapeutics Inc. logo
Beam Therapeutics Inc.BEAM · Nasdaq
4 assets: 3 Ph 2, 1 otherBEAM-301Phase 1/2 · Glycogen Storage Disease Type Ia30 Dec 2027BEAM-301 · Phase 1/2$2.2B$1.1BSep 2026~10.8 qtrs$409M
Celldex Therapeutics logo
Celldex TherapeuticsCLDX · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1barzolvolimabPhase 3 · Chronic Spontaneous UrticariaPartial signalMar 2027CDX-622 · Phase 1$2.2B$650MSep 2026~10.8 qtrs$283M
Immunome, Inc. logo
Immunome, Inc.IMNM ·
3 assets: 1 Ph 3, 2 Ph 1VaregacestatPhase 2/3 · Desmoid TumorsPartial signalMay 2027Varegacestat · Phase 1$2.0B$462MSep 2026~8.1 qtrs$227M
Harmony Biosciences logo
Harmony BiosciencesHRMY · Nasdaq
3 assets: 1 approved, 1 Ph 3, 1 otherClemizole (EPX-100)Phase 3 · Epilepsy30 Dec 2026Clemizole (EPX-100) · Phase 1$1.9B$771MSep 2026Cash-flow positive$238M
Biohaven logo
BiohavenBHVN · NYSE
7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1TroriluzolePhase 3 · Spinocerebellar AtaxiaPartial signalDec 2026Opakalim · Phase 2/3$1.9B$164MSep 2026~1.4 qtrs$428M
Trevi Therapeutics, Inc. logo
Trevi Therapeutics, Inc.TRVI · Nasdaq
1 asset: 1 Ph 3Nalbuphine ERPhase 3 · Chronic Cough in Idiopathic Pulmonary Fibrosis30 Nov 2026Nalbuphine ER · Phase 1$1.9B$299MSep 2026~19.5 qtrs$50M
F
First Tracks BiotherapeuticsTRAX · Nasdaq
1 asset: 1 Ph 2RosnilimabPhase 2 · Rheumatoid ArthritisNone on record$1.9B$156MSep 2026~5.7 qtrs~$117M
Replimune, Inc. logo
Replimune, Inc.REPL · Nasdaq
2 assets: 1 approved, 1 Ph 3Sturlimogene erparepvecPhase 2/3 · Uveal Melanoma1 Dec 2027Sturlimogene erparepvec · Phase 2$1.9B$310MSep 2026~4.6 qtrs~$195M
V
Vera Therapeutics, Inc.VERA · Nasdaq
1 asset: 1 approvedApproved assets onlyNov 2027Atacicept · Phase 2$1.8B$384MSep 2026~4.1 qtrs$247M
Ultragenyx Pharmaceutical Inc. logo
Ultragenyx Pharmaceutical Inc.RARE · Nasdaq
2 assets: 1 approved, 1 Ph 3setrusumabPhase 3 · Osteogenesis ImperfectaPartial signalJan 2027setrusumab · Phase 3$1.8B$266MSep 2026~2.4 qtrs$711M
Zymeworks logo
ZymeworksZYME · Nasdaq
2 assets: 2 approvedApproved assets only31 Dec 2026Zanidatamab · Phase 2$1.8B$100MSep 2026~3.6 qtrs$129M
Zenas BioPharma logo
Zenas BioPharmaZBIO · Nasdaq
1 asset: 1 Ph 3ObexelimabPhase 3 · IgG4-Related DiseasePartial signalNone on record$1.8B$585MSep 2026~9.6 qtrs$238M
AGIOS PHARMACEUTICALS, INC. logo
AGIOS PHARMACEUTICALS, INC.AGIO · Nasdaq
2 assets: 2 approvedApproved assets onlyMar 2029Mitapivat · Phase 3$1.8B$630MSep 2026~7.6 qtrs$343M

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415